|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||132.54 - 132.87|
|52 Week Range||102.79 - 132.87|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.20%|
There’s no question about it — growth stocks have been the place to be during this bull market. However, according to LPL analyst Burt White, the growth trade may have finally run its course in 2017 . ...
Becton Dickinson accelerated its strategy to establish itself as the leader in single cell genomics with its recent launch of BD Rhapsody, a single cell analysis platform.
Edwards Lifesciences (EW) had tremendous growth in the first half of 2017. The stock has been recovering from the lows in late 2016 and has recently been on a bullish trend.
Although Intuitive Surgical leads the surgical robotics market, there are competitive threats from other major players in the market.
Becton Dickinson (BDX) expects the CareFusion deal to result in cost synergies of $325.0 million to $350.0 million by 2018.
Year-over-year, Varian Medical Systems (VAR) expects its 4Q17 revenue to be flat or fall. According to the company, headwinds from the euro, British pound, and Japanese yen are expected to have…
Varian Medical Systems’ (VAR) oncology business reaches around the globe. With a market share of ~60%, It is a leading player in the space. Other major medical device companies in the…
To extend the durability of the Inspiris Resilia surgical aortic valve, Edwards Lifesciences (EW) has incorporated a new tissue platform, Resilia tissue.
To expand the market for TAVR therapy, Edwards Lifesciences (EW) has developed a three-pronged strategy that involves increasing awareness, expanding indications, and deploying advanced technology.
Stryker (SYK) expects the company's 2017 revenue to witness a YoY (year-over-year) rise of 6.5%–7% on an organic basis.
Ten analysts currently have active coverage on Wyndham Worldwide (WYN) stock. Of these analysts, 20% have “strong buy” recommendations on the stock.
In a Reuters survey of 28 brokerage firms, ~61% of the analysts rated Stryker as a “buy,” 29% rated it as a “hold,” and ~11% rated it as a "sell."
As of July 13, 2017, Intuitive Surgical’s stock was trading ~35.0% above its 52-week low of $610.7 on December 7, 2016.
BD is the leader in the flow cytometry devices market, which is a key growth subsegment in BD's Life Sciences segment.
Of the 29 analysts tracking Hilton stock, 79.3% (or 23 analysts) have "buy" ratings, 13.8% (or four analysts) have "hold" ratings, and 6.9% (or two analysts) have "sell" ratings ...
The average daily rate (or ADR) measures the average room price paid in the market. In 1Q17, the ADR rose 2.5% year-over-year (or YoY) to $124.27.
On June 6, 2017, Boston Scientific (BSX) announced the company had received CE Mark approval for its Vercise Gevia DBS (deep brain stimulation) systems.